covid novavax - Search News

Order byBest matchMost fresh

Novavax Soars

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 23h · on MSN

· 2d · on MSN

Novavax Soars After Covid Vaccine Secures Full FDA Approval

MPR · 3h

FDA’s New COVID-19 Vaccine Approval Policy May Limit Future Access

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

· 17h

· 18h

F.D.A. Poised to Restrict Access to Covid Vaccines

· 1d

US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant

WA vaccine scientists push back against FDA changes around COVID shots

According to the framework, published in the New England Journal of Medicine, new versions of the COVID vaccine — which have been developed annually to take into account emerging variants — will stil...

· 6h

· 1d

FDA sets new COVID booster guidelines for healthy adults under 65

· 21h

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

5hon MSN

Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.

FDA’s new approach raises questions about fall COVID vaccine availability

Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk.

18hon MSN

FDA sets new COVID booster guidelines for healthy adults under 65

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

2hon MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025.

Axios1d

New COVID booster rules could limit shots for people under 65

The policy change announced Tuesday will likely limit access to the shots to seniors and individuals with pre-existing conditions who are at higher risk of serious infections. The new approach under HHS Secretary Robert F.